CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 116 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00918684
NCT00918684Phase 4Completed
CompareCT.gov

Aging White Matter Changes, Executive Dysfunction and Depression

Weill Medical College of Cornell University·interventional·Posted Jun 11, 2009·Updated May 12, 2017

In Brief

A Phase 4 clinical trial evaluating Escitalopram for Depression. Completed, enrolled 116 participants.

Detailed Summary

The purpose of this study is to look at the relationship between age related structural brain changes and changes in depressive symptoms,disability and several aspects of cognitive functioning following treatment with escitalopram.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
Countries--
CollaboratorsNational Institute of Mental Health (NIMH), Forest Laboratories

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 11, 2009
Enrollment StartDec 1, 2002
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 17.1 years ago

Interventions

Escitalopramdrug

10mg tab daily